產(chǎn)品名稱：Z-LLY-FMK(CalpainInhibitor1)

Dissolve the Calpain Inhibitor 1 in DMSO before use.

For use on intact cells:
1. Prepare desired concentrated stock solutions as follows:
1 mg Z-LLY-FMK
in 9μl DMSO = 20 mM
in 18μl DMSO = 10 mM
in 36μl DMSO = 5 mM, etc.

2. Add 2 μL of above stock solution to 1 mL culture medium containing cells such that the fμl DMSO concentration is 0.2%. Levels of DMSO above this may cause some cellular toxicity, thus masking the effect of the Calpain Inhibitor 1. Adding 2 μL of a 10 mM stock solution to 1 mL of culture medium gives a final Z-LLY-FMK concentration of 20 μM.

For extended use in vivo or in vitro:
For experiments extending 12 to 48 hours, fresh inhibitor may have to be added (injected) due to inactivation of the inhibitor by endogenous cysteine proteases.
The calpains are calcium-activated neutral proteases whose activation leads to apoptosis in neurons. Many cellular processes are regulated by calcium and the activation of calpains by increased calcium in damaged neurons results in apoptosis, which contributes to spinal cord cell death in spinal cord injuries. In axons, calcium influx leads to a compacting of the cytoskeleton and an interruption of axonal transport, most likely through activation of calpains. Calpain I has three isoforms of 80, 78, and 76 kDa, whereas Calpain II is a single 176 kDa protein. Calpain I is activated during neuronal differentiation. Calpain II is activated during neurofibrillary degeneration, suggesting that the calpain system is involved in Alzheimer's Disease.